Actively Recruiting

Age: 18Years - 80Years
All Genders
NCT06303414

Revascularization for Symptomatic Non-acute Carotid Artery Occlusion

Led by Xuanwu Hospital, Beijing · Updated on 2024-03-12

1000

Participants Needed

2

Research Sites

654 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The short-term and long-term efficacy of recanalization therapy needs to be further confirmed by large-sample prospective studies. The comparison of success rate, complication rate and efficacy among the three recanalization modalities also needs to be further explored. The purpose of this cohort study is to observe the success rate, efficacy and safety of recanalization treatment for non-acute occlusion, and to further compare the advantages and disadvantages of CEA, endovascular intervention and hybrid surgery.

CONDITIONS

Official Title

Revascularization for Symptomatic Non-acute Carotid Artery Occlusion

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age older than 18 years
  • Signed informed consent form
  • Carotid artery occlusion lasting at least 24 hours
  • Presence of symptoms such as ischemia in the same side brain hemisphere, eye, or cognitive impairment, with or without infarction in the anterior circulation
  • Occlusion confirmed by digital subtraction angiography (DSA) at common or internal carotid artery with no flow (mTICI=0)
  • Perfusion imaging showing reduced blood flow (hypoperfusion) in the affected area
  • Patients receiving optimal medical treatment who still have ischemic symptoms
  • Routine diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) scans before surgery show no new infarction
Not Eligible

You will not qualify if you...

  • Presence of intracranial arteriovenous malformation or aneurysm
  • Unstable angina, myocardial infarction, or congestive heart failure within the last 6 months
  • Uncontrolled diabetes with blood glucose over 300 mg/dL (16.67 mmol/L)
  • Expected interruption of ADP antagonist therapy within 3 months after procedure
  • Pregnancy or perinatal period
  • Severe other diseases with life expectancy less than 3 years
  • Allergies or intolerance to aspirin, clopidogrel, or study medications
  • Allergy to iodine or contrast media
  • Vascular conditions preventing endovascular treatment
  • Large cerebral infarction within 2 weeks prior
  • History of vocal cord paralysis on the affected side
  • Severe skin diseases that may impair wound healing
  • Poor functional status before onset (mRS score 4-5)
  • Infarction area exceeding half of the vascular supply area
  • Existing dementia or psychiatric illness preventing neurological or cognitive assessments
  • Any condition making the patient unsuitable for surgery as judged by the surgeon

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100005

Actively Recruiting

2

Xuanwu Hospital, Capital Medical University.

Beijing, China, 100053

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here